Charged Alpha Stock Encyclopedia

Coupang, Inc. (CPNG) Q2 2026 — Reported Aug 4, 2026 BEFORE the open for Q2 2026 (quarter ended June 30). Revenue $8,856M, +3.9% YoY (+10% constant currency), vs ~$9,050M expected - a 2.2% MISS. GAAP EPS $(0.32) vs ~$(0.29). Adjusted EPS $(0.09) excludes $410M of Korean fines. Operating loss $(556)M. Adjusted EBITDA $163M, -62%. CPNG closed $16.78, +2.2%.

Every headline read 'Coupang beats EPS by 69%'. It didn't. The $410M PIPC fine was announced June 10 - eight weeks before the print - so consensus already carried it. Strip it out properly and the Street's underlying number was $(0.06); Coupang delivered $(0.09). That is a three-cent MISS. Revenue missed too, and Product Commerce - 84% of the company - saw adjusted EBITDA fall 42%.

THE CALL: AVOID (4/5, A CHEAP MULTIPLE ON A MARGIN THAT DOESN'T EXIST YET) — base-case value ~$10.75 vs ~$16.78 today.

KEY METRICS:

- CALL: AVOID 4/5, fair value ~$10.75 vs $16.78 - about 36% BELOW the price. Path-to-profitability DCF: FY2030E revenue $47.0B (7%/yr) x a 3.5% operating margin = $1,645M EBIT, $1,234M after 25% tax, plus $1.00B D&A less $1.50B capex plus a $350M working-capital release = $1,084M of free cash flow; 3% terminal growth at 9.5%, PLUS $3.60B net cash, over 1,792M shares = $9.35 base. Bear $8.00, bull $15.09. Only ONE of the nine cells in our grid reaches $16.78.

- THE BEAT NOBODY CHECKED: the $410M PIPC fines were announced June 10 - 20 days before the quarter closed and 8 weeks before the release - and were fully accrued in Q2. Consensus was ~$(0.29) INCLUDING them. $410M / 1,799M diluted shares = $0.2279, exactly the $0.23 per-share adjustment Coupang booked in its own reconciliation. $(0.29) less $(0.23) = an implied underlying $(0.06); Coupang delivered $(0.09). GAAP says the same: $(0.32) vs $(0.29). A three-cent MISS, not a 69% beat.

- THE CORE IS STALLING: Product Commerce is 84% of the company. Revenue +1% ($7,425M), gross profit -5% ($2,268M, margin -204bp to 30.5%), and segment adjusted EBITDA $382M vs $663M - DOWN 42%, margin from 9.04% to 5.15% (-389bp). The fine is NOT in that number; segment EBITDA excludes it. Developing Offerings (Eats, Play, fintech, Taiwan, Farfetch) actually improved: revenue +20%, gross profit +32%, EBITDA loss narrowed from $(235)M to $(219)M.

- REVERSE DCF: $16.78 x 1,792M = $30.1B equity, less $3.60B net cash = a $26.5B enterprise. Solve for the margin that closes the gap and you need ~$2.19B of 2030 free cash flow - about $3.1B of operating profit on $47.0B, a 6.6% OPERATING MARGIN. Coupang's operating income was $473M (2023), $436M (2024), $473M (2025) while revenue went $24.4B to $34.5B: +42% revenue, ZERO added operating profit. Best full year in four: 1.94%. Today: NEGATIVE 0.61%.

- CURRENCY, CASH AND WHAT'S NEXT: $8,524M x 1.10 = $9,376M vs $8,856M actual - a $520M FX drag worth 6.1 points of growth. Revenue per customer $301 (-2%) in USD, $321 (+5%) constant currency. ~$3.60B NET CASH - but they drew $750M on the revolver while spending $850M on buybacks, with TTM free cash flow of $105M (-87%). Still to come: the July Incheon warehouse fire (~$246M, hits Q3), a criminal trial, four US class actions, and a KFTC case that could unbundle Eats from WOW. STREET: consensus Buy, ~$26 target (+55%). We DIFFER.

What to watch: Changes our mind UP: Product Commerce adjusted EBITDA margin back above 7% for two straight quarters, or the won reverting far enough that reported growth catches constant currency. Confirms the bear: Commerce margin below 4.5%, another PIPC or KFTC penalty, or more buybacks funded by the revolver. Hard rule: if trailing FCF goes negative, we cut to a SELL. We would start buying under $11.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Arista Networks, Inc. (ANET) Q2 2026 — Reported Aug 4, 2026 AFTER the close for calendar Q2 2026 (quarter ended June 30). Revenue $3,035.7M, +37.7% YoY, vs ~$2.83B expected - a 7.3% beat and its first $3B quarter. Non-GAAP EPS $1.02 vs $0.89 (+14.6%), up 39.7%. GAAP EPS $0.95 vs $0.70. GAAP operating margin 45.4%, a five-quarter high. Q3 guide ~$3.3B, EPS $1.06-$1.08. ANET closed $190.51, a 52-week closing high - BEFORE the print.

Arista beat revenue by 7%, earnings by 15%, and beat its OWN May guidance by 8.4% (vs 4.2% last quarter). Operating margin hit a five-quarter high of 45.4% even though gross margin FELL 232bp, because opex leverage beat mix loss. But at $190.51 the enterprise is $229.7B against ~$4.46B of 2026 owner earnings - 51.6x, a 1.9% cash yield, and zero of the nine cells in our grid reach the price.

THE CALL: AVOID (4/5, AN ELITE BUSINESS AT AN IMPOSSIBLE PRICE) — base-case value ~$105.0 vs ~$190.51 today.

KEY METRICS:

- CALL: AVOID 4/5, fair value ~$105 vs $190.51 - about 45% BELOW the price. Ten-year owner-earnings DCF: FY2026E revenue ~$12.55B (H1 $5,744.7M + Q3 guide $3.3B + our $3.5B Q4) x the 44.1% GAAP operating margin H1 delivered, less the 19.4% tax paid = ~$4.46B of owner earnings, compounding 25% fading to 6% by 2035 ($41.8B), margin 35.5% to 30.5%, 10.5% discount rate (beta 1.615), 3.5% terminal. Enterprise $118.4B; ADD $13.34B net cash (zero debt) over 1,276.0M diluted shares = $103. Grid at 9.5/10.5/11.5%: bear $75/$66/$60, base $120/$103/$90, bull $184/$154/$132. ZERO of nine cells reach the price.

- REVERSE DCF: $190.51 x 1,276.0M = $243.1B equity, less $13.34B net cash = a $229.7B enterprise - 51.6x the ~$4.46B of 2026E owner earnings, a 1.9% cash yield. Solve for the growth that closes the gap at 10.5% and you need revenue compounding 43% next year fading to 11%: about $90B of revenue in 2035, ~1.5x Cisco's entire $56.7B today. Trailing GAAP P/E 60x; forward non-GAAP ~46x.

- THE BEAT NOBODY FRAMED: consensus was $0.89 EPS / ~$2.83B revenue, and Arista's OWN May guide was ~$2.8B. It delivered $3,035.7M - beating its own guide by 8.4%, double the 4.2% guide-beat in Q1. Revenue accelerated five straight quarters: $2,204.8M, $2,308.3M, $2,487.8M, $2,709.0M, $3,035.7M (+19%, +27%, +29%, +35%, +38% YoY).

- WHAT THE HEADLINE HIDES: GAAP gross margin 62.9% vs 65.2% (-232bp) as the AI mix dilutes price, yet operating margin ROSE to 45.4% because opex leverage (299bp) beat it. H1 operating cash flow $2,776.5M less $84.2M capex = $2,692.3M FCF - but $1,493.5M (55%) was the deferred-revenue build, i.e. customer prepayment; ex-that, H1 cash was ~$1,199M vs $2,235.8M of net income. Buybacks: $0 vs $983.0M a year ago.

- THE STALE FY GUIDE: the May full-year guide was $11.5B and Tuesday's release updated only Q3. H1 $5,744.7M + Q3 guide $3,300M = $9,044.7M, so $11.5B implies a Q4 of $2,455M - a 26% sequential COLLAPSE, below Q4 2025's $2,487.8M. It has to go up; our arithmetic says ~$12.5B. Deferred revenue +27.8% in six months to $6,865.9M. Cash + securities $13.34B, ZERO debt.

- STREET: 52 analysts - 39 buy, 13 hold, 0 sell; consensus Buy, average target $192.31 (range $164-$220), only ~1% above the price. We DIFFER and are far more CAUTIOUS on the price while AGREEING on the business.

What to watch: Changes our mind UP: gross margin stabilising above 63% for two straight quarters with growth above 30%. Confirms the bear: gross margin below 62%, the deferred-revenue build reversing, or a hyperscaler disclosing a material in-house fabric move. Hard rule: Q3 revenue under the $3.3B guide and we go to a full SELL. We would start buying under $120 (the March low was $116.13).

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Leidos Holdings, Inc. (LDOS) Q2 2026 — Reported Aug 4, 2026 BEFORE the open, for fiscal Q2 2026 - the 4-4-5 quarter ended JULY 3 (not June 30). Revenue $4,558M, +7% (+4% organic) vs ~$4,437M expected. Non-GAAP EPS $3.26 vs $2.91 - a 12.0% beat, but only +1.6% on $3.21 a year ago. GAAP EPS $2.81, DOWN 7%. FCF $761M vs $457M. Bookings $4.9B, book-to-bill 1.1, backlog $48.7B, funded backlog +44%. FY26 guidance raised again. LDOS closed $130.60, UP 10.0% - still 35% below its $199.55 high.

Leidos beat 12%, raised guidance and jumped 10% - and non-GAAP net income still FELL 1.4%, from $417M to $411M. Diluted shares went 130M to 126M, so at a flat share count EPS would have been $3.16, a DECLINE. The buyback did all of it, and the buyback is fading. Adjusted EBITDA margin dropped 140bp to 13.8% and operating income FELL 10% on revenue up 7%, because Health - 24% of revenue but 44% of segment profit at a 23.4% margin - shrank 8%.

THE CALL: BUY (4/5, PRICED FOR DECLINE, BOOKING FOR GROWTH) — base-case value ~$165.0 vs ~$130.6 today.

KEY METRICS:

- CALL: BUY 4/5, fair value ~$165 vs $130.60 - ~26% upside. Enterprise FCF DCF: H1 FCF $1,031M ($1,094M OCF less $63M capex); FY26 guided OCF ~$1.85B so ~$1.72B FCF, we model $1.70B growing 3.5% for three years then 2.5%, 2% terminal, 9% WACC. $7.26B of PV + $18.76B discounted terminal = a $26.01B enterprise; less $5.28B net debt over 125.5M shares = $165. Grid at 8/9/10%: bear $120/$101/$86, base $200/$165/$139, bull $255/$209/$175. A 25/45/30 weighting gives $162. SEVEN of nine cells sit ABOVE the price.

- REVERSE DCF: $130.60 x 125.5M = $16.39B equity, +$5.28B net debt = a $21.67B enterprise. Against ~$1.72B of 2026E FCF that is 12.6x and a 10.5% FCF yield - at a 9% WACC it implies FCF compounding at just 1.0% a year FOREVER, below inflation. The stock is 10.6x the midpoint of Leidos' OWN raised FY26 EPS guidance, ~9.1x EV/EBITDA, net debt 2.2x EBITDA, beta 0.55.

- THE BEAT IS AGAINST A CUT BAR AND THE GROWTH IS THE SHARE COUNT: $3.26 vs $2.91 is a 12.0% beat, but Leidos earned $3.21 a year ago - consensus modelled a 9% DECLINE, so real growth was 1.6%. Non-GAAP net income $411M vs $417M, DOWN 1.4%; diluted shares 126M vs 130M, and at a flat count EPS is $3.16, a decline. GAAP EPS $2.81 DOWN 7%; operating income $514M vs $571M, DOWN 10%. Adjusted EBITDA margin 13.8% from 15.2%. Buybacks were only $72M vs $537M in H1 last year, so that tailwind is fading.

- THE HEALTH CLIFF: segment operating income was I&D $142M, Health $254M, Homeland $92M, Defense $84M. Health is 44% of that on 24% of revenue at a 23.4% margin, vs 8.8-9.5% elsewhere - so to replace its $254M a quarter at Defense margins you need ~$2.9B of QUARTERLY revenue, 3x Health's entire $1,086M base. Health fell 8% as a FOURTH vendor phased onto the VBA medical exam contract, and backlog is $6.6B vs $8.0B, DOWN 18%. Entrust cost $2.34B in March; debt went $4.65B to $6.03B.

- BOOKINGS - THE PART NOBODY READ: $4.9B booked, book-to-bill 1.1, backlog $48.7B, FUNDED backlog UP 44% to $10.2B, Defense backlog +30%. Street: 27 analysts, 16 buy / 11 hold, target $165.88 - we got $165 independently, so we ALIGN. Source: 8-K EX-99.1 accession 0001336920-26-000243.

What to watch: Confirms it: more Homeland-style margin expansion and the $10.2B of funded backlog converting. Breaks it: a Health decline steeper than the fourth-vendor effect, losing the VBA recompete, or the DHA health-record decision going against Leidos. Hard rule: adjusted EBITDA margin below 13% and we cut to HOLD. Add aggressively under $115.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Amgen Inc. (AMGN) Q2 2026 — Reported August 4, 2026 AFTER the US close, for the calendar quarter ended June 30, 2026. Total revenue $10,054M, +10% YoY vs ~$9,426M expected. Non-GAAP diluted EPS $6.29 vs $5.62 expected - an 11.9% beat - but only +4% against $6.02 a year ago. GAAP diluted EPS $4.37, up 65% from $2.65. Free cash flow $3,489M vs $1,911M. FY2026 guidance RAISED for the second time: revenue $38.2-39.4B (from $37.1-38.5B) and non-GAAP EPS $22.30-23.50 (from $21.70-23.10). AMGN closed the regular session at $390.02, up 2.94% into the print, 1% below its record close of $393.10 on July 28.

Amgen beat by 11.9% and raised full-year guidance twice - and underneath it, non-GAAP EPS grew just 4%, because consensus had modelled a 7% DECLINE from last year's $6.02. Non-GAAP operating margin FELL half a point to 48.4% on revenue up 10%. The guidance raise was smaller than the beat: Amgen beat by $0.67 and lifted the full-year midpoint by $0.50, so with H1 at $11.44 the guide implies $11.46 in H2 - dead flat on rising revenue. Meanwhile debt outstanding went UP $2.7B in six months, to $57.3B from $54.6B at the year end, and there were ZERO share repurchases in the quarter against $1.4B of dividends. And the denosumab cliff arrived: Prolia -32% and XGEVA -34%, together $1,111M against $1,654M a year ago - $543M gone in one quarter, a $2.2B annual run-rate hole - while Enbrel's net selling price fell 22% under IRA Medicare Part D price setting.

THE CALL: HOLD (3/5, A GOOD QUARTER, ALREADY IN THE PRICE) — base-case value ~$356.0 vs ~$390.02 today.

KEY METRICS:

- CALL: HOLD 3/5. Fair value ~$356 against a $390.02 close - about 9% of downside. This is NOT a call against Amgen; the quarter was good and the portfolio transition is working. It is a call against paying a record price for 4% earnings growth. Method: a ten-year levered free-cash-flow DCF. H1 free cash flow was $4,966M ($6,191M operating cash flow less $1,225M capex); we carry FY2026 at ~$10.5B, growing 5% for five years then 3% for five, 2% terminal, discounted at an 8.5% cost of equity. Because this cash flow is measured AFTER interest, the result is already equity value - no net debt subtracted, or you double count. PV of ten years $85.9B plus discounted terminal value $107.8B = $193.7B over 544M diluted shares = $356. Grid at 7.5/8.5/9.5%: bear $330/$279/$243, base $423/$356/$307, bull $540/$453/$388. A 25/55/20 weighting also gives $356. Note honestly: FOUR of those nine cells sit ABOVE the price. This is a fair-value call, not a bubble call.

- REVERSE DCF - WHAT $390.02 REQUIRES: 544M diluted shares x $390.02 = $212.2B of equity. Holding everything else, that needs free cash flow compounding at about 6.5% a year for five years instead of 5% - against the 4% non-GAAP EPS growth Amgen just delivered and the 4.8% its own FY2026 guidance implies (midpoint $22.90 vs $21.85 in 2025). Or, holding our growth, it needs a cost of equity of 7.95% for a company carrying $43.3B of net debt into a denosumab cliff. On enterprise value ($212.2B equity + $43.3B net debt = $255.5B) the stock trades at 24.3x our FY2026E free cash flow, a 4.95% free cash flow yield, 17.0x forward non-GAAP EPS and 23.7x GAAP EPS - the non-GAAP figure adds back roughly $6.08 a share of acquisition amortisation.

- THE BEAT IS AGAINST A FALLING BAR: $6.29 vs $5.62 is an 11.9% beat, but Amgen earned $6.02 in the same quarter last year, so consensus had modelled a 7% DECLINE. Real growth was 4%. Revenue grew 10% ($10,054M vs $9,179M) while non-GAAP operating income grew only 7% ($4,612M vs $4,293M) and the non-GAAP operating margin FELL 0.5 points to 48.4%. The non-GAAP tax rate rose from 14.2% to 15.6%. GAAP operating income was $3,514M (36.8% of product sales, +6.5 points) and GAAP net income $2,375M. Product sales were $9,537M, +9%, all of it volume.

- THE GUIDANCE RAISE IS SMALLER THAN THE BEAT: FY2026 non-GAAP EPS guidance went $21.60-23.00 (February) to $21.70-23.10 (April) to $22.30-23.50 now - a midpoint of $22.40 to $22.90, up $0.50 after a $0.67 beat. H1 non-GAAP EPS was $11.44, so the full-year midpoint implies $11.46 in H2: dead flat, on revenue guided a full $1.0B higher at the midpoint ($37.8B to $38.8B). Management is signalling continued margin compression, and the MariTide Phase 3 programme is the reason. Capex guided ~$2.6B; buybacks capped at $3.0B with none used yet.

- THE DENOSUMAB CLIFF IS HERE: Prolia $759M, DOWN 32% (volume -20%, net price -12%) and XGEVA $352M, DOWN 34% (volume -22%, price -8%) - same molecule, denosumab, with biosimilars launched globally and, in Amgen's words, more expected. Together $1,111M vs $1,654M = $543M lost in one quarter, a $2.2B annual run-rate hole. Add Otezla $491M (-21%), Enbrel $580M (-4% but net selling price -22% from IRA Medicare Part D price setting effective Jan 1, plus 340B mix), KYPROLIS $314M (-17%) and MVASI $153M (-20%): about $2.65B of quarterly sales versus $3.45B a year ago, down 23%. That is roughly a quarter of product sales in structural decline.

- AND YET IT GREW 10%, BECAUSE THE NEW PORTFOLIO IS WINNING: the six key growth drivers grew 26% and are nearly 70% of product sales; 22 products grew double digits and 17 annualise above $1B. Repatha $953M (+37%), EVENITY $714M (+38%), TEZSPIRE $486M (+42%), UPLIZNA $335M (+90%), IMDELLTRA/IMDYLLTRA $288M (+115%), PAVBLU $287M (+121%), BLINCYTO $472M (+23%), TEPEZZA $576M (+14%), KRYSTEXXA $400M (+15%), Nplate $430M (+17%), TAVNEOS $150M (+36%), Vectibix $338M (+11%), LUMAKRAS $111M (+23%), AMJEVITA $155M (+17%).

- THE BALANCE SHEET NOBODY CHECKED: debt outstanding was $57.3B at June 30 ($5,445M current + $51,859M long-term), UP $2.7B from $54.6B at December 31 - after falling from $60.1B at the end of 2024. Cash rose to $14.0B from $9.1B, so net debt fell only about $2.2B, to $43.3B - roughly 4.1x our FY2026E free cash flow. Total shareholders' equity is $11,688M on $95,639M of assets, a 12% equity ratio. Dividends paid $1.4B at $2.52 a share (+6%); share repurchases in the quarter: NONE. The dividend alone consumes about 52% of estimated FY2026 free cash flow. FY2025 free cash flow was $8.1B, DOWN from $10.4B in 2024.

- MARITIDE IS THE WHOLE OPTION: MariTide (maridebart cafraglutide) activates GLP-1 and antagonises GIPR, pitched on dosing - monthly to start and as few as 4 or 6 doses a year to stay on. Running now: MARITIME-1 and -2 in weight management, MARITIME-CV, MARITIME-HF, MARITIME-OSA-1, MARITIME-SWITCH (off weekly tirzepatide or semaglutide), plus two long-term extensions; three more Phase 3s in type 2 diabetes start in 2026 and a Phase 2b in liver fat is enrolling. That is an enormous R&D bill and it is exactly why margin is compressing. In this same release Amgen DISCONTINUED future development of AMG 513, its other obesity asset - there is no back-up. The Phase 2 data everyone extrapolates from showed up to about 20% weight loss at 52 weeks, at the low end of expectations with tolerability-driven discontinuations. Our base case assigns MariTide essentially nothing.

- WHY WE DIFFER FROM WALL STREET - AND AGREE WITH ITS ARITHMETIC: 38 analysts cover Amgen (22 buy, 13 hold, 3 sell) and the consensus rating is Buy, with an average twelve-month target of $365.08 in a range of $303 to $427. Tuesday's close was $390.02 - so the Street's own average target sits 6% BELOW the price it rates a Buy. Our fair value is $356, theirs $365; those are the same answer. We simply call a stock 9% above fair value a HOLD, and we are modestly more CAUTIOUS because a flat second-half guide after a big beat is the more important sentence in this release. SOURCING: every figure is read off the 8-K EX-99.1 filed 2026-08-04, accession 0000318154-26-000124, grepped for 'Amgen' and 'June 30, 2026' before any number was taken; prior-guidance comparisons come from the Q1 2026 (0000318154-26-000054) and FY2025 (0000318154-26-000003) releases. Share count is off the filing (544M diluted), not FMP.

What to watch: Bullish (what would change our mind fastest): a MARITIME-1 or MARITIME-2 readout showing competitive weight loss on genuinely monthly or quarterly dosing - that alone makes this model far too conservative. Also constructive: a single quarter where non-GAAP operating margin stops falling. Bearish: another leg down in Prolia and XGEVA without the growth drivers accelerating. Level: we would buy under $330, roughly 15% below our fair value, where the dividend yield reaches about 3.1%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Space Exploration Technologies Corp. (SPCX) Q2 2026 — Reported August 4, 2026 AFTER the US close - the first-ever quarterly report as a public company, for the calendar quarter ended June 30, 2026. Revenue $7,814M, +92% YoY, versus roughly $6.93B expected. Diluted loss per share $0.09 versus a $0.26 loss modelled. Net loss $541M, narrowed from $1,008M. Adjusted EBITDA $3,538M, +191%. All three segments beat: Connectivity $4,291M (+66%), AI $2,561M (+247%), Space $962M (+29%). But capital expenditure was $18,369M in the quarter - 235% of revenue, up more than six-fold from $2,825M, and about $5B above the ~$13.2B the Street had modelled. SPCX closed the regular session at $125.33, up 9.43%, then fell in extended trading. IPO priced at $135.00 on June 11 and began trading June 12. Closing high $201.80 (Jun 16); all-time closing low $108.37 (Jul 31).

SpaceX beat on every line Wall Street actually models - and the stock fell anyway, because the number that moved it is not on the income statement. Capital expenditure was $18.37 BILLION in one quarter against $7.81 billion of revenue: $2.35 of capital spending for every $1 of sales, up more than six-fold year over year, with $15.83B of it in AI alone - 618% of the AI segment's own revenue. First-half operating cash flow was $3.47B against $28.48B of capex, so free cash flow for the half was NEGATIVE $25.0 billion. Three things almost nobody has connected. FIRST, only ONE of the three segments makes money: Connectivity earned $1,656M of operating income at a 38.6% margin, and it pays for $1,799M of losses in Space and AI combined. SECOND, AI's celebrated first-ever positive Adjusted EBITDA of $1,146M is a depreciation artifact - $23.55B of H1 AI capex adds roughly $4.7B a year of depreciation on a five-year life, more than the entire figure being celebrated. THIRD, Starlink subscribers DOUBLED to 12.0 million while ARPU fell 22%, from $85 to $66; consumer revenue rose only 44% against 100% subscriber growth, so revenue per subscriber fell about 28%. And two trading days after this print, on August 6, the first lock-up tranche frees roughly 911 million shares - 143% of the entire IPO float.

THE CALL: AVOID (1/5, A REMARKABLE COMPANY AT AN IMPOSSIBLE PRICE) — base-case value ~$32.0 vs ~$125.33 today.

KEY METRICS:

- CALL: AVOID 1/5. Fair value ~$32 against a $125.33 close - 74% below. This is NOT a call against SpaceX the company; the quarter was genuinely strong and the engineering is unmatched. It is a call against this price. Method: a ten-year path-to-profitability DCF, because there is no free cash flow to discount. Base case: revenue compounds 25% a year for a decade, $30B in 2026 to $283B in 2035; capex plateaus near $100B; 2035 free cash flow $55B (a 19% margin). Discounted at 9.5% with 3% terminal growth: $846B terminal value, $374B discounted back nine years, less $21B for the negative interim cash flows, plus $61B net cash, over 13,176M shares = $31. Grid at 8.5/9.5/10.5%: bear $15/$12/$10, base $39/$31/$26, bull $86/$68/$55. A 30/50/20 weighting gives $33. EVERY cell is below the price - including the bull case at the friendliest discount rate we would defend.

- REVERSE DCF - WHAT $125.33 REQUIRES: 13,176M shares (Class A 7,607M + Class B 5,569M off the June 30 balance sheet) x $125.33 = $1,651B of equity; less $61B of net cash ($100.0B cash and marketable securities against $39.4B of debt and finance leases) = $1,591B of enterprise value. At 9.5% and 3% terminal growth that needs roughly $256 BILLION of free cash flow in 2036. At a generous 25% free-cash margin that is $1.02 TRILLION of revenue - a level no company has ever reached - and a 42% compound growth rate for ten straight years off today's $31B annualised run-rate. On that run-rate the stock trades at 51x sales and 112x even the flattering annualised Adjusted EBITDA.

- THE CAPEX SHOCK, WHICH IS THE WHOLE STORY: $18,369M of capital expenditure in one quarter against $7,814M of revenue = 235% of revenue, up from $2,825M a year ago (more than six-fold) and $10,107M last quarter. By segment: AI $15,828M, Connectivity $1,367M, Space $1,174M. AI capex alone was 618% of AI segment revenue. Consensus had modelled roughly $13.2B, so the miss was about $5B. First half: operating cash flow $3,466M against capex $28,476M, so first-half free cash flow was NEGATIVE $25.0B. Net property, plant and equipment went from $42.6B at the year end to $65.7B in six months. Nameplate compute reached 1.4 GW, up from 0.4 GW a year ago.

- ONLY ONE SEGMENT MAKES MONEY: Connectivity (Starlink) revenue $4,291M, +66%, with income from operations of $1,656M - a 38.6% operating margin and Adjusted EBITDA of $2,597M. Space revenue $962M, +29%, but a LOSS from operations of $542M, because Starship R&D alone was $1,076M in the quarter. AI revenue $2,561M, +247%, but a LOSS from operations of $1,257M. So Starlink's $1,656M of profit funds $1,799M of losses elsewhere, and the difference is the $143M consolidated operating loss on the headline. Total R&D was $3,548M - 45.4% of revenue, up 81% year over year.

- THE ADJUSTED EBITDA PROBLEM: the $3,538M headline excludes depreciation, amortisation, share-based compensation, interest and tax - in other words, it excludes the cost of the one thing this company is spending all of its money on. D&A was $2,848M in the quarter against $1,526M a year ago, up 87%, and it is about to accelerate: $23,551M of H1 AI capex on a five-year life adds roughly $4.7B a year of depreciation once in service. That is MORE than AI's celebrated first-ever positive Adjusted EBITDA of $1,146M. AI's GAAP loss from operations was still $1,257M. Segment Adjusted EBITDA: Connectivity $2,597M, AI $1,146M, Space negative $205M.

- THE STARLINK NUMBER NOBODY QUOTED: 12.0 million subscribers, double a year ago and up 1.7 million sequentially - but ARPU is $66 a month against $85 a year ago, a 22% DECLINE, reported flatly with no commentary. Consumer revenue rose 44% ($1,721M to $2,485M) against 100% subscriber growth, so revenue per subscriber fell roughly 28%. Growth is being bought with price. Enterprise and government revenue, up 108% to $1,806M, is now doing the heavy lifting - helped by over $6B of multi-year Starshield contracts and FCC approval of the EchoStar spectrum transfer.

- THE LOCK-UP, TWO DAYS AFTER THIS PRINT: SpaceX used a STAGGERED lock-up, not a single 180-day one, and the first tranche is triggered by this earnings report. On August 6 insiders may sell up to roughly 911 million shares - about $114B at the $125.33 close, 143% of the entire 638,888,888-share IPO float, and roughly eight full days of the ~111.5M average daily volume. A further tranche of about 28% follows the Q3 print, with the full period ending December 8. Elon Musk's shares carry a 366-day lock-up into June 2027. The stock is already 46% below its June 16 closing high of $201.80 and 7% below the $135.00 IPO price.

- BALANCE SHEET AND CAPITAL STRUCTURE: cash and equivalents $93,522M plus marketable securities $6,487M = $100.0B, against debt and finance leases of $39,364M ($2,525M current, $36,839M long-term) - net cash of $60.6B. Backlog $47.5B and $14.1B of newly contracted Cloud Services Agreements. Total assets $192,770M; shareholders' equity $127,224M; accumulated deficit $41,852M. Note the related-party exposure: $13.3B of the debt is related-party, and $327M of the $629M quarterly interest expense is related-party. The IPO closed June 15 (638,888,888 Class A shares, ~$85.7B net proceeds) and a $25B inaugural investment-grade bond issue closed June 26 across five tranches at 5.35%-6.65%, a 5.855% weighted average.

- WHY WE DIFFER FROM WALL STREET: consensus is Buy with an average twelve-month target of $214 (range $115 to $401), about 71% above the $125.33 close. Morgan Stanley initiated Overweight at $300; Goldman Sachs at $205; every initiation since the IPO has been buy-equivalent. We are at ~$32 and we say so on the slide. The gap is method, not facts: the sell-side is valuing SpaceX on a 2030-2035 sum of the parts with venture-scale multiples attached, while we discount cash - and on that basis the capital spending is not an asset, it is a decade of deferred free cash flow, and it is still accelerating. We might be the ones who are wrong, and we say that on the slide too. SOURCING NOTE: every figure above is read off the 8-K Item 2.02 EX-99.1 filed 2026-08-04 (accession 0001628280-26-052515), grepped for the company name and for 'June 30, 2026' before any number was taken. CIK 0001181412 was verified independently on EDGAR. The share count is off the consolidated balance sheet, not FMP.

What to watch: Bullish (what would change our mind fastest): a quarter in which AI capital expenditure FLATTENS while AI revenue keeps compounding. That single data point would make this model far too bearish and we would say so. Also constructive: Starship reaching operational reusability and the Space segment turning profitable. Bearish: another quarter where capex grows faster than revenue. Level: we would start looking under $60, roughly twice our base-case value.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Atkore Inc. (ATKR) Q3 FY2026 — Reported August 3, 2026 BEFORE the US open for fiscal Q3 2026 - the 13-week quarter ENDED JUNE 26, 2026 (not June 30; Atkore runs a 13-week fiscal quarter and a September 30 fiscal year end). In the SAME release Atkore announced a definitive agreement to be acquired by Prysmian S.p.A. for $95.00 per share in ALL CASH, an enterprise value of about $3.8 billion. Net sales $794.8M, +8.1% YoY. Adjusted EBITDA $104.7M, +4.7%. Adjusted diluted EPS $1.92 vs $1.63. GAAP diluted EPS just $0.02 vs $1.25, on net income of $0.745M, after a $50.0M litigation settlement. The stock closed August 3 at $93.55, up 28.2% on the announcement session, versus the $72.96 unaffected close of July 31. It closed August 4 at $93.53. The 12-month closing low was $53.85 on August 11, 2025. Guidance was withdrawn and the earnings call was cancelled because of the pending transaction.

The deep-value versus value-trap debate on Atkore got settled - not by the cycle, but by a buyer. Prysmian, the Milan-listed cable maker, is paying $95.00 a share in cash, a 30% premium to the $72.96 unaffected close and 57% above the $60.69 close of September 29, 2025, the last trading day before Atkore announced its strategic review. Both boards approved unanimously, there is NO financing condition, and the deal is targeted to close by calendar year end 2026. Three things almost nobody has connected. FIRST, the cycle turned one quarter BEFORE the sale: trailing twelve-month adjusted EBITDA fell from $561.8M (March 2025) to $321.0M (March 2026), a 43% collapse, and then ticked UP to $325.8M this quarter - the first increase in six quarters. Quarterly it has gone $70.9M, $69.1M, $81.1M, $104.7M. Prysmian bought the bottom. SECOND, the buyback arithmetic: Atkore spent $1.61 BILLION on its own stock across fiscal 2021-2025 - half the $3.21B equity cheque Prysmian is writing for the entire company - retiring a net 12.27 million shares for about $120 of cash each, against a $95 exit. THIRD, the $186.5M of PVC antitrust settlements booked in nine months equal 57% of a full year of current earnings power: the super-cycle is being partially refunded.

THE CALL: AVOID (2/5, THE DEAL ALREADY PAID YOU) — base-case value ~$84.0 vs ~$93.53 today.

KEY METRICS:

- CALL: AVOID 2/5. This is NOT a call against Atkore or against the deal. If you own the stock, vote for the merger and take the $95.00 - it is a good price and the board earned it. This is a call against putting NEW money in at $93.53. Standalone fair value ~$84 on normalized owner earnings. Normalized adjusted EBITDA $400M (23% ABOVE the $325.8M trailing twelve months, 48% BELOW fiscal 2024's $771.7M): less $100M D&A, less $29M net interest, taxed at 24%, add back D&A, less $70M maintenance capex = $236M of owner earnings, or $6.99 per share on the 33,772,550 shares on the 10-Q cover. At 12x, or as a perpetuity at a 10% discount rate with 1.5% terminal growth, that is ~$84. Bear $63 / base $84 / bull $117 at 10%; a 30/50/20 probability weighting also gives ~$84. The signed deal at $95.00 is about 13% ABOVE our standalone number - which is exactly what a strategic buyer with synergies is supposed to pay.

- THE ARBITRAGE, WHICH IS THE WHOLE TRADE NOW: $95.00 deal versus a $93.53 close is $1.47, a 1.57% gross spread. Add the two permitted $0.33 quarterly dividends (the next is payable August 28, 2026) and total value to a year-end close is $95.66, about 2.3%, or roughly 5.5% annualised. Against that, the unaffected price is $72.96 - a break costs about 22%. Assuming a break takes the stock to roughly $78, the market at $93.53 is implicitly pricing an 88% chance of closing. We think the true probability is nearer 95% - unanimous boards, no financing condition, modest product overlap - but even AT 95% the expected value is only about $94.80, which annualises to roughly 3% and lands BELOW Treasury bills. You are risking $20 to make $1.47. We would want to pay under $91.

- REVERSE DCF - WHAT $95.00 ACTUALLY REQUIRES: $95.00 on 33.77M shares is $3,208M of equity. At a 10% discount rate and 1.5% terminal growth that needs $269M of owner earnings, which back-solves to roughly $443M of normalized adjusted EBITDA - 36% ABOVE the $325.8M trailing figure and 15% above fiscal 2025's $386.4M. Prysmian is underwriting that recovery PLUS its own synergies, and as a strategic it is entitled to. At $93.53 you would be underwriting it WITHOUT the synergies, for 1.6%. Enterprise value check: $3,208M equity + $414.0M net debt + $153.3M of lease obligations = $3,775M, which reconciles to the 'approximately $3.8 billion' the company states, or 11.6x trailing adjusted EBITDA. At the $72.96 unaffected price the same math is 9.3x.

- THE QUARTER, WHICH WAS GENUINELY THE BEST IN TWO YEARS: net sales $794.8M (+8.1%), with volume +$65.7M, average selling prices +$22.4M - positive for the first time in years - FX +$8.0M, less $39.0M from divestitures. Adjusted EBITDA $104.7M (+4.7%), up sequentially for the second straight quarter. Adjusted diluted EPS $1.92 vs $1.63. BUT gross margin fell 120bps to 22.2% because input costs rose $48.9M against only $22.4M of price: Atkore is finally getting price and is STILL losing the spread. Segments: Electrical $578.3M (+10.9%, volume +$62.8M) with adjusted EBITDA $89.3M at a 15.4% margin (down 20bps); Safety and Infrastructure $216.8M (+1.3%, price +$8.7M but volume only +$2.9M) with adjusted EBITDA $28.1M at 13.0%, DOWN 140bps and down 8.4% in dollars on higher revenue.

- WHAT THE HEADLINE HIDES: adjusted EPS was $1.92 but GAAP diluted EPS was $0.02, on net income of $745 thousand, down 98.3%. The gap is a $50.0M litigation settlement plus $9.8M of transaction costs and a $12.7M loss on a divestiture. Across nine months, settlements total $186.5M and Atkore is $108.3M in the red. The cash statement is worse and almost nobody read it: nine-month operating cash flow was NEGATIVE $90.3M against POSITIVE $192.4M a year ago, and free cash flow was NEGATIVE $130.7M against POSITIVE $107.4M - driven by a $163.4M receivables build and a $60.2M tax outflow. Capex was halved to $40.4M from $84.9M. Cash fell from $506.7M to $346.2M and net debt rose from $253.8M to $414.0M, still only 1.3x trailing adjusted EBITDA.

- THE CYCLE TURNED ONE QUARTER BEFORE THE SALE (the under-covered fact): trailing twelve-month adjusted EBITDA, straight off the net-debt table in the release - $561.8M (Mar 2025), $455.6M (Jun 2025), $386.4M (Sep 2025), $356.4M (Dec 2025), $321.0M (Mar 2026), then $325.8M (Jun 2026). That last figure is the FIRST increase in six quarters. Quarterly: $70.9M, $69.1M, $81.1M, $104.7M. Atkore announced its strategic review on September 30, 2025 with the stock at $60.69; trailing earnings troughed in the March 2026 quarter; the merger was signed August 2, 2026. Revenue tells the same story: $1,916.5M (FY19), $1,765.4M (FY20), $2,928.0M (FY21), $3,913.9M (FY22 peak), $3,518.8M (FY23), $3,202.1M (FY24), $2,850.4M (FY25) - and nine-month fiscal 2026 is +4.0%, the first growth since 2022.

- THE BUYBACK NOBODY IS ADDING UP: Atkore spent $135.1M (FY21), $500.2M (FY22), $491.0M (FY23), $381.0M (FY24) and $100.0M (FY25) on its own stock - $1.607 BILLION, or roughly HALF the $3.21B equity cheque Prysmian is writing for the whole company. The 10-K cover share count went from 46,016,923 (Nov 2021) to 33,750,486 (Nov 2025), so $1.472B across fiscal 2022-2025 retired a net 12.27 million shares: about $120 of cash per net share retired, against a $95.00 exit. Ex post that is roughly $307M of value transferred to exiting holders - about $9 per share still outstanding. In fairness, fiscal 2022 operating income was $1.234B and the stock looked cheap on every multiple; the error was mistaking a super-cycle for a base. Buybacks stopped entirely in fiscal 2026: zero.

- PAYING THE SUPER-CYCLE BACK: the single largest line in Atkore's fiscal 2026 income statement is not a business expense - it is $186.5M of litigation settlements in In re PVC Pipe Antitrust Litigation (N.D. Illinois). Two putative classes settled April 28, 2026 ($136.5M) and the third, the End User Plaintiffs, settled June 3, 2026 for $50.0M. That $186.5M equals 57% of a full year of Atkore's CURRENT earnings power. Set it against the window at issue: revenue went from $1.77B (FY2020) to $3.91B (FY2022) and operating income from $239.6M to $1,233.8M - a 31% operating margin on conduit. The settlements carry no admission, but the investment point stands. Separately, note that the data-center narrative both companies lead with is NOT a disclosure: Atkore reports two segments and zero data-center revenue.

- WHY WE ALIGN WITH THE STREET: consensus is Hold across 4 analysts at an average target of $82.33 - but most of that average is STALE. KeyBanc's $70 (Overweight) and Loop Capital's $65 (Hold, cut from $115) were set BEFORE anyone knew a deal existed. The only refreshed post-deal number is Roth/MKM, which downgraded to Neutral and RAISED its target to $92 - still BELOW the $95.00 deal price. A sell-side analyst looking at a signed, all-cash, no-financing-condition transaction still would not mark the stock to the deal; that is the same discount for time and closing risk we are charging. We ALIGN on Hold and are more CAUTIOUS on the spread. Sourcing note: CIK 0001666138 was verified independently on EDGAR (0001521722 is the WRONG Atkore entity), and the 8-K EX-99.1, the 10-Q and the merger 8-K were each grepped for 'Atkore' (32, 50 and 58 hits) and for the period before any number was read. The share count is off the 10-Q COVER PAGE, not FMP.

- DEAL TERMS YOU SHOULD KNOW: $95.00 per share in cash; merger agreement signed August 2, 2026 with Prysmian S.p.A. (BIT: PRY), Trinity Merger Sub Inc. and guarantor Prysmian Cables and Systems USA LLC. Enterprise value about $3.8B. Unanimous board approval on both sides. NO financing condition - Prysmian represents it will have sufficient funds, funded by a mix of debt including hybrid bonds and equity including treasury share disposal, targeting to preserve its investment-grade profile. Conditions: majority shareholder vote, HSR expiry, plus clearances in Austria, Australia and Canada. End Date August 3, 2027, with two automatic three-month extensions for regulatory delay. Company termination fee $115,920,000 for a superior proposal or a board recommendation change. Atkore may keep paying a quarterly dividend of up to $0.33. Citi is lead financial advisor with J.P. Morgan; Debevoise and Plimpton is legal advisor.

- PRICE AND POSITION CONTEXT: $93.53 at the August 4 close, on 33,772,550 shares (10-Q cover, July 31, 2026) for a market capitalisation of $3.159B, computed from the filing rather than taken from FMP. The 12-month closing range is $53.85 (August 11, 2025) to $93.55 (August 3, 2026, the announcement session). The 50-day average is $76.82 and the 200-day $69.19. Atkore is a Delaware corporation headquartered in Harvey, Illinois, run by CEO Bill Waltz, with 5,400 employees and $2.9B of fiscal 2025 sales. Balance sheet at June 26, 2026: cash $346.2M, total debt $760.2M, net debt $414.0M, total equity $1,276.2M, and a new $54.0M equity method investment. Guidance was withdrawn and the scheduled earnings call cancelled; a call was held August 7 only because the indenture on the Senior Notes due 2031 requires one.

What to watch: Bullish (we would take the spread): a price under $91, which is roughly a 13% annualised return to a year-end close and finally pays for the break risk. Also constructive: a competing bid, though the non-solicit and a $115.92M company termination fee make one unlikely. Bearish: a second request from the FTC or DOJ, which pushes closing past year end - and note there is NO reverse termination fee disclosed for a regulatory failure, so the $115.92M break fee runs only in the buyer's favour. On a break, the reference point is the $72.96 unaffected close, roughly 22% below today.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Rockwell Automation, Inc. (ROK) Q3 FY2026 — Reported Aug 4, 2026 pre-open, fiscal Q3 ended June 30, 2026. Sales $2,313M (+8% reported, +10% organic) beat ~$2,245M est. ADJUSTED EPS $3.49 BEAT ~$3.38 (+22% YoY); GAAP diluted EPS $3.65. FY26 guidance RAISED. Stock -7.9% to $442.84.

Rockwell grew organic sales 10%, adjusted EPS 22%, and raised full-year guidance on both lines - and the stock fell 7.9%. Two reasons. First, the raise is currency: the FY26 organic sales growth midpoint went up ~150bp and Rockwell disclosed ~150bp of favourable FX inside the same outlook, and the new $13.00-$13.30 EPS range BRACKETS the $13.02 consensus. Second, organic ARR - the recurring book a 33.7x multiple is paying for - grew just 6%, guided to mid-single digits all year, while the hardware grew 10%.

THE CALL: HOLD (2/5, A GREAT COMPANY AT A PRICE THAT NEEDS 12% COMPOUNDING FROM A 6% RECURRING BOOK) — base-case value ~$360.0 vs ~$442.84 today.

KEY METRICS:

- CALL: HOLD 2/5 - fair value ~$360 vs $442.84 (-19%). Enterprise DCF on free cash flow. FY26 base $1,470M (Rockwell guides ~100% FCF conversion of adjusted income; $13.15 guidance midpoint x 111.6M diluted shares = $1,468M), corroborated by TTM FCF of $1,504M read off the release's own quarterly table. Base: 8.25% WACC, 9% FCF growth FY27-31, 6% FY32-36, 3.0% terminal = $348. Bear $264, bull $485; 30/50/20 = $345. Cross-checks: 26x ~$14.70 FY27E EPS = $382; 21x ~$2,082M FY26E adj EBITDA = $367. We carry $360.

- THE PRINT: sales $2,313M, +8% reported and +10% ORGANIC, vs ~$2,245M est - a BEAT. ADJUSTED EPS $3.49 vs ~$3.38 est and $2.85 a year ago, +22%. GAAP diluted EPS $3.65 on $408M of net income. Gross margin 49.5% (+70bp). Enterprise operating margin 22.3% (+280bp). Pre-tax margin 20.3% vs 16.0%. Free cash flow $654M vs $489M, a 167% conversion of adjusted income.

- WHY IT FELL - THE RAISE IS CURRENCY. FY26 organic sales growth guidance went 5-9% to 7.5-9.5%, a 150bp midpoint raise - and the updated outlook includes ~150bp of favourable currency. Adjusted EPS guidance went $12.50-$13.10 to $13.00-$13.30, but 11c of that is this quarter's beat and the new range BRACKETS the $13.02 consensus. Implied Q4: adjusted EPS $3.45-$3.75 (mid $3.60) vs ~$3.56 est, sales ~$2,394M vs ~$2,367M. In line - which on 33.7x is a de-rating.

- SEGMENTS + ARR: Software & Control $751M, +19% (+18% organic), 34.8% margin vs 31.6%. Intelligent Devices $1,080M, +12%, 20.0% margin vs 18.8%. Lifecycle Services $482M, -12% reported but only -2% ORGANIC (11pts is the Sensia divestiture), margin up to 15.1%. But ORGANIC ARR grew only 6%, software ARR high single digits, and FY26 organic ARR guidance is unchanged at MID-SINGLE DIGITS. The hardware is outgrowing the recurring book.

- QUALITY OF THE BEAT + REVERSE TEST: $0.37 of the $3.65 GAAP EPS is the Sensia JV dissolution ($0.17 gain + $0.20 discrete tax); ~40bp of the 280bp margin expansion is the same exit. The ADJUSTED tax rate went 15.3% to 19.2% on BEPS Pillar Two - a permanent FY27 headwind. Price/cost is negative in ALL THREE segments; 100bp of the 250bp of FY26 price is earnings-neutral tariff pricing. Net debt is a modest $2,779M (~1.3x). FY26 revenue guidance of ~$9,051M is FLAT vs FY2023's $9,058M while the shares are +42%. REVERSE TEST: at $442.84 the ~$52.1Bn enterprise requires FCF to compound at 12.4%/yr for 5 years and 8.3% for 5 more. STREET: Hold (12 buy / 25 hold / 2 sell of 39), average target $484.43 (high $525, low $430). We are CAUTIOUS - same rating word, we DIFFER on value.

What to watch: Bullish: organic ARR printing above 9% on Nov 5, with double-digit ARR inside the FY2027 guide, takes us to ~$420. Bearish: a Q4 miss on the implied $3.60 adjusted EPS / ~$2,394M of sales, or an FY2027 guide that has to absorb 4 points of adjusted tax rate and negative price/cost without margin help, takes us to ~$290.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

NRG Energy, Inc. (NRG) Q2 2026 — Reported Aug 4, 2026 pre-open, quarter ended June 30, 2026. Revenue $7,481M (+11%) beat ~$7,312M est. ADJUSTED EPS $1.49 MISSED ~$1.69; GAAP EPS $2.32. Adj EBITDA $1,217M (+34%). FY26 guidance REAFFIRMED. Stock -15.4% to $117.13, a 52-week low.

NRG beat on revenue, grew adjusted EBITDA 34%, reaffirmed full-year guidance and announced a 1.2 GW gas plant for an AI hyperscaler - and the stock fell 15.4% to a 52-week low. The reason is on page 17 of the deck: NRG's guidance assumes $52/MWh Texas power, and the July 10 forward curve prints $40. Every year through 2030 is 8-23% below the assumption. We still think the sell-off overshot.

THE CALL: BUY (3/5, CHEAP FOR REASONS - AND THE REASONS ARE SURVIVABLE) — base-case value ~$140.0 vs ~$117.13 today.

KEY METRICS:

- CALL: BUY 3/5 - fair value ~$140 vs $117.13 (+20%). Equity DCF on FREE CASH FLOW TO EQUITY at the cost of equity (no debt add-back; FCFbG is already after ~$1.2Bn/yr of cash interest). Base = the $3,050M FY26 FCF-before-growth midpoint LESS the $686M of growth investment in NRG's own capital-allocation bridge ($416M data centre + $205M plant/consumer + $65M other) = $2,364M, or $11.24/share. Base 11.0% CoE / 1.75% terminal = $138; bear $102, bull $217; 30/50/20 = $143. At $140 that is 9.5x EV/2026E adj EBITDA and 15.7x the guided EPS midpoint.

- THE PRINT: revenue $7,481M (+11%) vs ~$7,312M est - a BEAT. ADJUSTED EPS $1.49 vs ~$1.69 est and $1.73 a year ago - a MISS. GAAP net income $506M, GAAP basic EPS $2.32 (vs a $104M loss last year). Adjusted EBITDA $1,217M, +34%. FCF before growth $1,025M. Adjusted EPS fell because the LS Power deal brought $305M of quarterly interest and $494M of D&A with it.

- WHY IT REALLY FELL - THE POWER CURVE. Deck slide 30 states the outlook assumption: ERCOT around-the-clock $52/MWh for 2026 and '$52 flat' for 2027-2030. Slide 17, same file, prints the actual curve at 7/10/2026: 2026 $40 vs $52 (-23%), 2027 $46 vs $59 (-21%), 2028 $50 vs $59, 2029 $52 vs $59, 2030 $54 vs $59. NRG's own sensitivity says a $45 ATC price costs the Texas book $150M hedged and $380M unhedged - and the out-years are the unhedged ones. PJM went the other way, +7-26%.

- SEGMENTS + BALANCE SHEET: Texas adj EBITDA $381M vs $512M, DOWN 26% (H1 $597M vs $811M). East $469M vs $99M - but $7,101M of cash bought it, plus PJM capacity clearing $325-333/MW-day (revenue $644M -> $729M -> $781M). Vivint $301M (+16%). Debt and finance leases $23,256M vs $162M of cash; net debt ~4.1x guided EBITDA vs 3.0x at VST and 2.6x at CEG. NRG cut $681M out of debt paydown to fund the plant.

- THE DATA CENTRE DEAL + REVERSE TEST: 1.2 GW CCGT, expandable to 2.4 GW, 15-year minimum term, investment-grade hyperscaler with a parent guarantee, ~95% of project cash flow from capacity payments not utilisation. $3.2Bn cost ($2,700/kW), ~$500M run-rate adj EBITDA and ~$375M FCFbG, 12-15% IRR, a 6.4x build multiple against NRG's own 8.7x trading multiple. But status is only 'Commercial Terms Aligned' and first power is late 2029. REVERSE TEST: at $117.13 the ~$24.5Bn equity requires FCF to equity to grow just 1.3% a year forever. STREET: Buy (14/2/1 of 17), average target cut to ~$198 from $202 (high $267, LOW $99). We DIFFER - same side, far less upside.

What to watch: Bullish: definitive documentation / FID on the 1.2 GW BYOP project (today it only reads 'commercial terms aligned') takes us to ~$165. Bearish: the ERCOT 2027 strip staying below $46, or a November quarter that fails to close the $2.98-vs-$7.90-9.90 guidance gap, takes us to ~$100.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Zebra Technologies Corporation (ZBRA) Q2 2026 — Reported Aug 4, 2026 pre-open for the quarter ENDED JULY 4, 2026. Net sales $1,557M, +20.4% (organic +9.2%). GAAP EPS $4.85; NON-GAAP EPS $6.35 vs ~$4.36 est. FY26 guide raised to $20.75-$21.25. Stock +22.7% to $357.85.

Zebra beat by almost two dollars and raised full-year guidance by $2.50 - and the stock ripped 22.7%. But $2.00 of that raise is just the quarter it already reported beating its own guidance; the SECOND HALF went up about fifty cents. And $1.23 of the $6.35 is a one-time tariff refund, with management guiding EBITDA margin from 27.7% back to ~22% next quarter.

THE CALL: TRIM (3/5, A GOOD QUARTER AT A PRICE THAT NEEDS A BETTER ONE) — base-case value ~$295.0 vs ~$357.85 today.

KEY METRICS:

- CALL: TRIM 3/5 - fair value ~$295 vs $357.85 (-18%). Equity DCF on LEVERED FCF at the cost of equity (no debt add-back). Base FCF $970M = the FY26 guide of >$1.0B less the ~$59M after-tax tariff recovery. 5.5% fading to 4%, 2.75% terminal, 10.5% CoE = $293; bear $226, bull $327; 20/50/30 = $295. On 48,129,265 diluted shares (mkt cap $17,222M).

- THE PRINT (quarter ENDED JULY 4, 2026 - a 52/53-week year): net sales $1,557M, +20.4% but only +9.2% ORGANIC, vs ~$1,497M est. Gross margin 53.0% vs 47.6%. GAAP EPS $4.85; NON-GAAP EPS $6.35 vs ~$4.36 est. Adj EBITDA $431M (27.7% vs 20.6%). Connected Frontline $903M (+7.5% organic); Asset Visibility & Automation $654M (+11.4%).

- THE RAISE IS 80% BACKWARD-LOOKING. On May 12 Zebra guided FY26 to $18.30-$18.70 (mid $18.50) and Q2 to $4.20-$4.50 (mid $4.35); Q1 actual $4.75 - so the OLD implied 2H was $9.40. Today FY goes to $20.75-$21.25 (mid $21.00) and 1H actual is $11.08, so the NEW implied 2H is $9.92. The guide rose $2.50, but $2.00 is just Q2 beating its own midpoint. The forward outlook improved ~50 CENTS. The stock rose 22.7%.

- $1.23 OF THE $6.35 IS A TARIFF REFUND. The release discloses IEEPA tariff recoveries of $73M, only $14M received, and credits the 540bp gross-margin jump to those recoveries and FX. $73M at the guided 19% rate = $1.23/sh, ~45% of the $2.74 YoY EPS rise; another ~12 pts is a 6.1% smaller share count. Q3 guide: EBITDA margin ~22% vs 27.7%, EPS $4.70-$4.90 vs $6.35.

- BALANCE SHEET + REVERSE TEST: cash $157M vs total debt $2,776M; CURRENT debt jumped to $2,275M from $141M, so working capital is NEGATIVE $1,936M. Goodwill $4,701M > equity $3,435M. H1 FCF $361M vs $568M of buybacks. At $357.85 the equity ($17,222M) needs ~10% FCF growth for 5 years then 2.75% forever - vs 6-8% ORGANIC guidance and a 2.0% revenue CAGR since 2021. STREET: Buy 19/8/0, target raised to ~$365 (+2%). We DIFFER, more CAUTIOUS.

What to watch: Bullish: Q3 (Nov) adjusted EBITDA margin at 24%+ vs the ~22% guided moves us to ~$340. Bearish: memory cost inflation hitting FY27 gross margin, or the $2,275M of now-current debt refinancing well above its coupon, takes us to ~$250.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

BioNTech SE (BNTX) Q2 2026 — Reported Aug 4, 2026 pre-open for the three and six months ended June 30, 2026. Revenue EUR 105.6M, DOWN 59.5%. Net loss EUR 820.8M, more than DOUBLE the EUR 386.6M a year ago. FY2026 revenue guidance CUT from EUR 2.0-2.3B to EUR 1.6-1.9B. The ADR opened at $89.18, fell to $88.20, then reversed to $93.245 (+1.1%). ADS ratio 1:1; EUR/USD 1.1526.

BioNTech cut 2026 revenue guidance by 400 million euros, doubled its quarterly loss, and wrote its COVID manufacturing equipment down to a recoverable value of ZERO - and the stock finished UP. That is not irrational: 80% of the market cap is net cash, so the whole 14-trial oncology pipeline is priced at about $4.6 billion.

THE CALL: HOLD (3/5, THE CASH IS THE FLOOR - THE PIPELINE IS THE PRICE) — base-case value ~$79.0 vs ~$93.245 today.

KEY METRICS:

- CALL: HOLD 3/5 - fair value ~$79/ADS vs $93.245 (-15%). ADS RATIO 1:1 (the release states each ADS represents one ordinary share); EUR/USD 1.1526, cross-checked against the company's own Q2 buyback translation ($89.50 / EUR 77.85 = 1.1497). Vendor per-share data on ADRs is per-ADS in USD while the release is per-ordinary-share in EUR, so the P&L is rebuilt from the release; market cap from the cover page: 251,204,366 x $93.245 = $23,424M.

- THE PRINT: revenue EUR 105.6M vs EUR 260.8M (-59.5%). Net loss EUR 820.8M vs EUR 386.6M. IFRS diluted LPS EUR (3.24) vs (1.60); adjusted EUR (2.22) vs (1.45). R&D EUR 551.0M (adjusted EUR 477.1M after EUR 73.9M of impairments). SG&A EUR 197.8M vs EUR 137.4M, +44%.

- THE GUIDANCE CUT IS BIGGER THAN THE HEADLINE: FY26 revenue cut from EUR 2,000-2,300M to EUR 1,600-1,900M (-19% at the midpoint). H1 was EUR 223.7M, so the implied H2 is EUR 1,376-1,676M - and the company says the EUR 613M Bristol Myers Squibb collaboration revenue lands in Q3, i.e. 37-45% of the ENTIRE second half in one accounting entry. Strip it and the underlying business is guided to ~EUR 1.0-1.3B for the year. Reasons: softer COVID demand; Germany using existing inventory; a milestone slipping past 2026.

- THE COVID FUNERAL: Q2 vaccine revenue EUR 51.9M vs EUR 153.3M (-66%), vs more than EUR 17B in 2022. For the FIRST time non-COVID revenue (EUR 53.7M) was the larger half. BioNTech capitalised the decline: EUR 87.0M of impairments at Marburg and Idar-Oberstein, of which EUR 68.9M of equipment had a recoverable amount 'determined to be zero'. Marburg is the plant it bought from Novartis in 2020 to make 750M doses a year.

- VALUATION - SUM OF THE PARTS, NOT A DCF (no owner earnings to discount): cash and securities EUR 16,634.2M less EUR 316.1M of leases/loans = $18,808M = $74.87/ADS, 80% of the market cap (the 6-K also discloses BioNTech believes it is a PFIC). Charge the burn, ~$4.9B in PV to 2030, and you get $55.36/ADS. Add the risk-adjusted pipeline - pumitamig $2.8B (40% on a $6B peak, 50/50 with BMS), the ADCs and gotistobart $1.8B, residual COVID/mRNA/CureVac $1.5B = $24.28/ADS. Total $79.64; 25/50/25 weighting $79.07. REVERSE TEST: EV is ~$4,616M, so the price implies a $9,516M pipeline, 56% above what we carry. VS THE STREET: Buy, 21/3/0, avg $132.71 (low $96 - even that is ABOVE the price); they see +42%, we see -15%. We DIFFER and are more CAUTIOUS. CIK 0001776985.

What to watch: Bullish: a clean DYNASTY-Breast02 readout in HER2-low breast cancer, due Q4 2026, moves us toward $105. Bearish: the EUR 613M BMS revenue not landing in Q3, or pumitamig's Phase 3 survival data failing to separate - either takes us to ~$58.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.